Assessment and Impact of Comorbidity in Older Adults with Cancer

  • Athanasios Karampeazis
  • Martine Extermann

Cancer is increasing with age. Almost 60% of cancers and two thirds of cancer deaths occur beyond the age of 65 years in developed countries [1]. Due to the aging of the population, this proportion is expected to increase in the future. Older patients present with increased concomitant diseases. In a geriatric series, people 65 years of age and older suffer on average from three different diseases, and, similarly, older cancer patients present a high level of comorbidity [2–5]. Furthermore, comorbidity does not appear to correlate closely with either tumor stage or functional status. Therefore, comorbidity should be assessed independently [3].


Axillary Lymph Node Dissection Breast Conservative Surgery Comorbid Disease Charlson Index Charlson Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Yancik R, Ries LA. Cancer in older persons. Cancer 1994;74:1995–2003.PubMedCrossRefGoogle Scholar
  2. 2.
    Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of comorbidity with disability in older women: The Women’s Health and Aging Study. J Clin Epidimiol 1999;52:27–37.CrossRefGoogle Scholar
  3. 3.
    Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582–7.PubMedGoogle Scholar
  4. 4.
    Yancik R, Wesley M, Ries L, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc 2001;285:885–92.CrossRefGoogle Scholar
  5. 5.
    Koroukian S, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 2006;24:2304–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622–6.PubMedGoogle Scholar
  8. 8.
    Miller MD, Towers A. A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). University of Pittsburgh, May 1991.Google Scholar
  9. 9.
    Greenfield S, Apolone G, McNell BJ, et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip after hip replacement. Med Care 1993;31:141–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidities in evaluating the outcome of diabetes mellitus. J Chron Dis 1974;27:387–404.PubMedCrossRefGoogle Scholar
  11. 11.
    Piccirillo JF, Costas I, Claybour P, et al. The measurement of comorbidity by cancer registries. J Registry Manage 2003;30:8–14.Google Scholar
  12. 12.
    Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med Care 1996;34:1093–101.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Parmelee PA, Katz IR, Lawton MP. The relation of pain to depression among institutionalized aged. J Gerontol 1991;46:P15–P20.Google Scholar
  17. 17.
    Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995:43:130–7.PubMedGoogle Scholar
  18. 18.
    Krousel-Wood MA, Abdoh A, Re R. Comparing comorbid-illness indices assessing outcome variation: The case of prostatectomy. J Gen Intern Med 1996;11:32–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Clemens JD, Feinstein AR, Holabird N, et al. A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancer. J Chron Dis 1986;39:913–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Pompei P, Charlson ME, Ales K, et al. Relating patient characteristics at the time of admission to outcomes of hospitalization. J Clin Epidimiol 1991;10:1063–9.CrossRefGoogle Scholar
  21. 21.
    Piccirillo JF. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology 1995;9:831–6.PubMedGoogle Scholar
  22. 22.
    Piccirillo J, Tierney R, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. J Am Med Assoc 2004;291:2441–7.CrossRefGoogle Scholar
  23. 23.
    Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, Deeg HJ, Appelbaum FR, Storer B, Storb R. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 2007;110(13):4606–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD9-CM in administrative databases. J Clin Epidemiol 1992;45:613–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Romano PS, Roos LL, Luft HS, Jolly JG, Doliszny K. A comparison of administrative versus clinical data: Coronary artery bypass surgery as an example. J Clin Epidemiol 1994;47:249–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57(12):1288–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53(12):1258–67.PubMedCrossRefGoogle Scholar
  29. 29.
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17(8):584–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Extermann M. Interaction between comorbidity and cancer. Cancer Control 2007;14;13–22.PubMedGoogle Scholar
  32. 32.
    Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: Influence on patient care and outcome. Eur J Cancer 2007;43:2179–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Vulto A, Lemmens V, Louwman M, et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer 2006;106:2734–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. J Am Med Assoc 1987;257:2766–70.CrossRefGoogle Scholar
  35. 35.
    Firat S, Pleister A, Byhardt R, et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III non-small cell lung cancer (NSCLC). Am J Clin Oncol 2006;29:252–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Asmis T, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trial Group trials. J Clin Oncol 2008;26:54–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:1047–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529–36.PubMedGoogle Scholar
  39. 39.
    Tammemagi M, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer 2003;103:792–802.PubMedCrossRefGoogle Scholar
  40. 40.
    Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005;23:6865–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Juan O, Albert A, Campos J, et al. Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. Acta Oncologica 2007;46:367–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Gonlugur TE, Gonlugur U. Comorbidity as a prognostic factor in small cell lung cancer. Tumori 2006;92:423–8.PubMedGoogle Scholar
  43. 43.
    Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104–10.PubMedGoogle Scholar
  44. 44.
    Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–17.PubMedGoogle Scholar
  45. 45.
    Cronin-Fenton DP, Norgaard M, Jacobsen J, et al. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 2007;96:1462–8.PubMedGoogle Scholar
  46. 46.
    Reld B, Alberg A, Klassen A, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer 2001;92:2109–16.CrossRefGoogle Scholar
  47. 47.
    Yancik R, Wesley M, Ries L, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. Cancer 1998;82:2123–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;109:1376–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12(9):954–64.PubMedCrossRefGoogle Scholar
  50. 50.
    Meyerhardt J, Catalano P, Haller D, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21:433–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Polednak A. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: A population-based study. Cancer Detect Prev 2006;30:466–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003;98:484–95.PubMedCrossRefGoogle Scholar
  53. 53.
    Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114. J Clin Oncol 2004;22:648–57.PubMedCrossRefGoogle Scholar
  54. 54.
    Pavelka J, Brown R, Karlan B, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006;107:1520–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Tretli S, Haldorsen T, Ottestad L. The effect of pre-morbid height and weight on the survival of breast cancer patients. Br J Cancer 1990;62:299–303.PubMedCrossRefGoogle Scholar
  56. 56.
    Kimura M. Obesity as prognostic factors in breast cancer. Diabetes Res Clin Pract 1990;10:S247–S251.PubMedCrossRefGoogle Scholar
  57. 57.
    Coates RJ, Clark WS, Eley JW, et al. Race, nutritional status and survival from breast cancer. J Natl Cancer Inst 1990;82:1684–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Vatten LJ, Foss OP, Kvinnsland S. Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking: A population-based study. Eur J Cancer 1991;27:641–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Senie RT, Rosen PP, Rhodes P, et al. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 1992;116:26–32.PubMedGoogle Scholar
  60. 60.
    Bastarrachea J, Hortobagyi GN, Smith TL, et al. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1993;119:18–25.Google Scholar
  61. 61.
    Katoh A, Watzlaf VJM, D’Amico F. An examination of obesity and breast cancer survival in post-menopausal women. Br J Cancer 1994;70:928–33.PubMedCrossRefGoogle Scholar
  62. 62.
    Obermair A, Kurz C, Hanzal E, et al. The influence of obesity on the disease-free survival in primary breast cancer. Anticancer Res 1995;15:2265–70.PubMedGoogle Scholar
  63. 63.
    Zhang S, Folsom AR, Sellers TA, et al. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. Cancer 1995;76:275–83.PubMedCrossRefGoogle Scholar
  64. 64.
    Haybittle J, Houghton J, Baum M. Social class and weight as prognostic factors in early breast cancer. Br J Cancer 1997;75:729–33.PubMedCrossRefGoogle Scholar
  65. 65.
    Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 2001;20:42–51.CrossRefGoogle Scholar
  66. 66.
    Hammarsten Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887–95.Google Scholar
  67. 67.
    Mikuls T, Endo J, Puumala S, et al. Prospective study of survival outcomes in non-Hodgkin’s lymphoma patients with rheumatoid arthritis. J Clin Oncol 2006;24:1597–602.PubMedCrossRefGoogle Scholar
  68. 68.
    Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 2005;16:1795–800.PubMedCrossRefGoogle Scholar
  69. 69.
    Gronberg B, Sundstrom S, Jordhey M. The prognostic value of comorbidity assessed using the cumulative illness rating scale for geriatrics in patients with advanced non-small cell lung cancer. J Clin Oncol 2008;26; abstr 9506.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Medical OncologistArmy General Hospital of AthensAthensGreece
  2. 2.Department of Medical OncologyUniversity General Hospital of HeraklionHeraklionGreece
  3. 3.H. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations